361 related articles for article (PubMed ID: 33308321)
1. Post-translational modifications of EZH2 in cancer.
Li Z; Li M; Wang D; Hou P; Chen X; Chu S; Chai D; Zheng J; Bai J
Cell Biosci; 2020 Dec; 10(1):143. PubMed ID: 33308321
[TBL] [Abstract][Full Text] [Related]
2. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
Lu H; Li G; Zhou C; Jin W; Qian X; Wang Z; Pan H; Jin H; Wang X
Am J Cancer Res; 2016; 6(12):2737-2754. PubMed ID: 28042497
[TBL] [Abstract][Full Text] [Related]
3. PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression.
Wan J; Zhan J; Li S; Ma J; Xu W; Liu C; Xue X; Xie Y; Fang W; Chin YE; Zhang H
Nucleic Acids Res; 2015 Apr; 43(7):3591-604. PubMed ID: 25800736
[TBL] [Abstract][Full Text] [Related]
4. Regulation and Role of EZH2 in Cancer.
Yamaguchi H; Hung MC
Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
[TBL] [Abstract][Full Text] [Related]
5. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic.
Guo Y; Cheng R; Wang Y; Gonzalez ME; Zhang H; Liu Y; Kleer CG; Xue L
EBioMedicine; 2024 Feb; 100():104972. PubMed ID: 38244292
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
Biomark Res; 2018; 6():10. PubMed ID: 29556394
[TBL] [Abstract][Full Text] [Related]
7. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
8. Targeting EZH2 for cancer therapy: progress and perspective.
Han Li C; Chen Y
Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
[TBL] [Abstract][Full Text] [Related]
9. The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials.
Richard SA; Eugene KD
Anal Cell Pathol (Amst); 2021; 2021():4907167. PubMed ID: 34745848
[TBL] [Abstract][Full Text] [Related]
10. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
Marchesi I; Bagella L
World J Clin Oncol; 2016 Apr; 7(2):135-48. PubMed ID: 27081636
[TBL] [Abstract][Full Text] [Related]
11. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.
Jarome TJ; Perez GA; Hauser RM; Hatch KM; Lubin FD
J Neurosci; 2018 Aug; 38(35):7635-7648. PubMed ID: 30030400
[TBL] [Abstract][Full Text] [Related]
13. Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control.
Pandey M; Sahay S; Tiwari P; Upadhyay DS; Sultana S; Gupta KP
Toxicol Appl Pharmacol; 2014 Oct; 280(2):296-304. PubMed ID: 25168426
[TBL] [Abstract][Full Text] [Related]
14. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
16. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
17. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Huang JP; Ling K
Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
[TBL] [Abstract][Full Text] [Related]
18. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
20. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]